Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib + Durvalumab in 2L FGFR2+ Biliary Tract Cancer
NCT06530823Phase 2Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Antibody Conjugates
01
Overview
A Phase 2 trial of pemigatinib, durvalumab in cholangiocarcinoma (CCA), gallbladder cancer, sponsored by Eastern Hepatobiliary Surgery Hospital. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
pemigatinibdurvalumab
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NCT06530823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530823.